Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | GRN | P28799 | 5/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13539048 | 0.83 | BAZ2B (0.35) | POLBAPEX1TDP1L3MBTL1MEN1 | |
| SCHEMBL22403096 | 0.82 | LMNA (0.41) | POLBAPEX1TDP1L3MBTL1MEN1 | |
| SCHEMBL15519140 | 0.79 | POLB (0.46) | POLBAPEX1TDP1L3MBTL1HDAC4 | |
| SCHEMBL11633601 | 0.75 | ALDH1A1 (0.46) | POLBAPEX1TDP1L3MBTL1ALOX15 | |
| SCHEMBL335459 | 0.71 | — | — | |
| SCHEMBL4600805 | 0.71 | PTGS2 (0.49) | POLBTDP1L3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5395245 | 0.70 | RAB9A (0.53) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL8095132 | 0.69 | — | — | |
| SCHEMBL8079706 | 0.68 | HSP90AA1 (0.45) | POLBAPEX1TDP1L3MBTL1HDAC4 | |
| Hydrazine SCHEMBL3522472 | 0.68 | RAB9A (0.51) | POLBMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521238-B | Preparation method of N-methyl-2- (2-chloroethyl) pyrrolidine | 甘肃瀚聚药业有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-115521238-B | Preparation method of N-methyl-2- (2-chloroethyl) pyrrolidine | 甘肃瀚聚药业有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-115521238-B | Preparation method of N-methyl-2- (2-chloroethyl) pyrrolidine | 甘肃瀚聚药业有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-101636476-B | Composition, method and purposes | INNOSPEC LTD. (GB) | 2015-08-12 | — | — | CN | disclosed |
| US-7645761-B2 | Indoline derivatives | WYETH (US) | 2010-01-12 | — | — | US | disclosed |
| US-7608633-B2 | Heteroaryl-substituted acetone derivatives as inhibitors of phospholipase A2 | MERCKLE GMBH (DE) | 2009-10-27 | — | — | US | disclosed |
| EP-1590324-B1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A sb 2 /sb | MERCKLE GMBH (DE) | 2009-03-11 | — | — | EP | disclosed |
| US-20070259944-A1 | Indoline derivatives | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-7253203-B2 | Indoline derivatives | WYETH (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060142366-A1 | Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 | MERCKLE GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20030220388-A1 | Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents | WYETH | 2003-11-27 | — | — | US | disclosed |
| US-6608068-B2 | Substituted indoline derivative compounds which are antagonists of the progesterone receptor; contraceptives; antineoplastic agents | WYETH | 2003-08-19 | — | — | US | disclosed |
| US-6544970-B2 | Administering in a first phase of a progestational agent (levonorgestrel or ethinylestradiol) and in a second phase an antiprogestin that is an indolinone derivative, especially a 3-spiroalkylene derivative | WYETH | 2003-04-08 | — | — | US | disclosed |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2003-03-13 | — | — | US | disclosed |
| US-6462032-B1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2002-10-08 | — | — | US | disclosed |
| US-20020086874-A1 | Indoline derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-07-04 | — | — | US | disclosed |
| US-6391907-B1 | ANTICANCER AGENTS; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-1173212-A1 | CONTRACEPTIVE COMPOSITIONS CONTANING INDOLONE DERIVATIVES AND PROGESTATIONAL AGENTS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066167-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING INDOLINE DERIVATIVES AND PROGESTATIONAL AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142366-A1 | Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 | PLD2, PLA2G1B, PLA2G4A | POLB 2397/4885APEX1 3394/4885TDP1 2434/4885 |
| US-20070259944-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | POLB 4140/4885APEX1 2032/4885TDP1 2536/4885 |
| US-20020086874-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | POLB 4042/4885APEX1 1966/4885TDP1 2243/4885 |
| US-20030220388-A1 | Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents | PGR, CYP19A1, PGRMC1 | POLB 3154/4885APEX1 2382/4885TDP1 1992/4885 |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | PRLHR, GNRHR, BRCA1 | POLB 3515/4885APEX1 2385/4885TDP1 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.